Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)
Abstract Background/Objectives Unfortunately, not all metastatic castration resistant prostate
cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing …
cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing …
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
Background Breast and prostate tumors are known to be less responsive to immune
checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a …
checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a …
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations
PURPOSE There are limited data available on the real-world patterns of molecular testing in
men with advanced prostate cancer. We thus sought to evaluate next-generation …
men with advanced prostate cancer. We thus sought to evaluate next-generation …
[HTML][HTML] Assessing the role of MSH2 and MSH6 gene expression deficiency in prostate cancer progression, a cross-sectional study
Background Recently, some evidence emphasized the value of MSH2 and MSH6
inactivation and their hypermutation in predicting different cancers. The present …
inactivation and their hypermutation in predicting different cancers. The present …
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer
PC Barata, J Assayag, B Li, G Siu, A Niyazov - JAMA oncology, 2024 - jamanetwork.com
Methods| This cross-sectional retrospective study was based on anonymized secondary
data reported at the aggregated level and not at the patient level. The study was exempt …
data reported at the aggregated level and not at the patient level. The study was exempt …
[HTML][HTML] Updates in Precision Oncology in Prostate and Urothelial Cancer
JR Brown - International Journal of Cancer Care and …, 2024 - journal.binayfoundation.org
Basic science, translational, and clinical genomic advances in prostate and urothelial cancer
have therapeutic implications. Poly (ADP-ribose) polymerase (PARP) inhibitors target …
have therapeutic implications. Poly (ADP-ribose) polymerase (PARP) inhibitors target …
The Impact of PTEN and Other Tumor Suppressor Gene (TSG) Alterations on Clinical Outcomes in De Novo Metastatic Prostate Cancer: Observational Study From the …
B Thapa - 2024 - search.proquest.com
Background: Previous studies suggest tumor suppressor gene alterations are enriched
during metastatic prostate cancer disease progression and that compound alterations (ie,≥ …
during metastatic prostate cancer disease progression and that compound alterations (ie,≥ …
Assessment of blood-based tumor mutational burden on clinical outcomes in advanced breast and prostate cancer treated with immune checkpoint inhibitors
Background Breast and prostate are in general, less responsive to Immune checkpoint
inhibitors (ICIs). Tumor mutation burden (TMB) has emerged as a predictive biomarker of …
inhibitors (ICIs). Tumor mutation burden (TMB) has emerged as a predictive biomarker of …
Delaying Filgrastim Administration after Autologous Stem Cell Transplant in Patients with Multiple Myeloma
G Medawar, AP Rodriguez, C Cerio… - … Journal of Cancer …, 2022 - journal.binayfoundation.org
Aim The therapeutic progress achieved with pediatric regimens in childhood acute
lymphoblastic leukemia (ALL) has contributed to the increase of their use in adolescents and …
lymphoblastic leukemia (ALL) has contributed to the increase of their use in adolescents and …